Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Participants needed: 900
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Janssen-Cilag Ltd.Updated: Jul 31, 2026Locations: 68
Eligibility criteria

Have a documented diagnosis of multiple myeloma [+3]

To be excluded from REALiTEC cohorts if received teclistamab as part of an inter... [+2]

Read more
Status: Recruiting

A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants

This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Janssen-Cilag Ltd.Updated: Jul 6, 2026Locations: 1
Eligibility criteria

Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheum... [+4]

Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment. [+6]

Read more
Status: Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult participants with moderately to severely active Ulcerative Colitis (UC) or Crohn's Disease (CD) under real-world settings. CD and UC are the main type of Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

Participants needed: 220
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Janssen-Cilag Ltd.Updated: Jul 6, 2026Locations: 1
Eligibility criteria

Must be eligible for biologic treatment and initiate guselkumab according to the... [+2]

Contraindicated to guselkumab per the label [+4]

Read more